Skip to main content
Communities & Collections
Browse DSpace
Statistics
English
Türkçe
Log In
Log in
New user? Click here to register.
Have you forgotten your password?
Home
Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed
Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed
Permanent URI for this community
https://hdl.handle.net/20.500.14719/1741
Browse
Search
Subcommunities and Collections
By Issue Date
By Author
By Title
By Subject
By Subject Category
Search
Subcommunities and Collections
By Issue Date
By Author
By Title
By Subject
By Subject Category
1 results
Back to results
Filters
Author
search.filters.author.Aksoy, Berna
Subject
search.filters.subject.Human
1
search.filters.subject.Adult
1
search.filters.subject.adult
1
search.filters.subject.Adverse Effect
1
search.filters.subject.Aerosol
1
search.filters.subject.aerosol
Show more
Search subject
Submit
Browse subject tree
Date
Start
End
Submit
2017
1
Has files
1
No
Item Type
1
Publication
Type
search.filters.itemtype.Note
Reset filters
Settings
Sort By
Accessioned Date Descending
Most Relevant
Title Ascending
Date Issued Descending
Results per page
1
5
10
20
40
60
80
100
Search
End date: 2019
×
Subject: search.filters.subject.Human
×
Type: search.filters.itemtype.Note
×
Author: search.filters.author.Aksoy, Berna
×
Search Tools
Search Results
Now showing
1 - 1 of 1
No Thumbnail Available
Publication
Metadata only
Itraconazole-induced thrombocytopenia
(
Taylor and Francis Ltd
[email protected]
,
2017
)
Aksoy, Berna
;
Aksoy, Berna, Department of Dermatology, Bahçeşehir Üniversitesi, Istanbul, Turkey, Dermatology Clinic, VM Medicalpark Hospital, Kocaeli, Turkey
Show more
Itraconazole is one of the systemic treatment options for extensive tinea versicolor. A male patient who developed thrombocytopenia during the treatment of tinea versicolor by itraconazole is reported in this manuscript. He was diagnosed to develop thrombocytopenia on the third day of treatment. In the literature, there are two reports of itraconazole-induced thrombocytopenia both in malignancy patients. One report contained three patients who developed thrombocytopenia as a result of a drug interaction between bortezomib and itraconazole. The other report contained a patient who developed thrombocytopenia following six weeks of treatment with itraconazole. It is hypothesized by the author of this manuscript that this patient’s thrombocytopenia developed as a result of selective bone marrow suppression which is brought about by itraconazole’s effect on megakaryocytes. © 2017 Elsevier B.V., All rights reserved.
Show more